Nanofibers and their biomedical use by ROMANA ROŠIC et al.
Giant progress of nanoscience in the last decade has prompted the development of
new nanosystems as well as new technologies for their preparation. Polymer nanofibers
prepared by the electrospinning method are just one of such examples. These are solid
fibers with diameters from a few tens up to 1000 nm (Fig. 1) and theoretically unlimited
length having a huge surface area per unit mass and small pore size. All these parame-
ters strongly depend on the preparation process and hence can vary significantly. Pore
size for example is the crucial parameter when using nanofibers as tissue scaffolds or
wound dressings. Namely, when pores are smaller than the cell size, the cells are cap-
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The idea of creating replacement for damaged or disea-
sed tissue, which will mimic the physiological condi-
tions and simultaneously promote regeneration by pa-
tients’ own cells, has been a major challenge in the bio-
medicine for more than a decade. Therefore, nanofibers
are a promising solution to address these challenges. These
are solid polymer fibers with nanosized diameter, which
show improved properties compared to the materials of
larger dimensions or forms and therefore cause different
biological responses. On the nanometric level, nanofi-
bers provide a biomimetic environment, on the micro-
metric scale three-dimensional architecture with the de-
sired surface properties regarding the intended applica-
tion within the body, while on the macrometric scale me-
chanical strength and physiological acceptability. In the
review, the development of nanofibers as tissue scaf-
folds, modern wound dressings for chronic wound ther-
apy and drug delivery systems is highlighted. Research
substantiates the effectiveness of nanofibers for en-
hanced tissue regeneration, but ascertains that evidences
from clinical studies are currently lacking. Nevertheless,
due to the development of nano- and bio-sciences, prod-
ucts on the market can be expected in the near future.
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tured and their spreading across and through nanofibers is limited. Additionally, nano-
fibers express greater flexibility and mechanical strength compared to the same material
of other forms and larger dimensions (1, 2).
A bibliometric analysis in the Web of Science database picturesquely reveals the sig-
nificance of the interest in polymer nanofibers as the number of scientific publications
raises from only about a hundred at the beginning of the decade to more than 2500 in
2011 (Fig. 2) (3). The importance of nanofibers is further supported by the fact that the
global market for nanofibers in all industrial areas is estimated to have been worth 176
million dollars in the year 2012. The annual growth of the market is even expected to be
30 % despite the fact that there are only about 50 companies in the world involved in the
production of nanofibers (4).
Unique properties of nanofibers resulting from their structure coupled with the rela-
tive ease of their preparation technology extended the applicability of nanofibers in vari-
ous fields, but with the strongest emphasis on the development of nanofibers for medi-
cal purposes, air filtration and electronics (1, 5).
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Fig. 1. View of polymer nanofibers collected on an aluminum collector with: a) the naked eye and
b) magnified picture of the same sample under scanning electron microscope.
Fig. 2. Increase in the number of scientific publications from the nanofiber field during the period
2001–2011 (3).
USE OF NANOFIBERS IN THE BIOMEDICAL FIELD
Based on a literature survey, previous research in the biomedical field, which is the
subject of this review, can be classified into three groups, namely, the development and
usage of nanofibers as i) tissue scaffolds, ii) modern wound dressings and iii) drug de-
livery systems (5–8). Without any doubt nanofibers are a unique class of materials, since
on the nanometric level they provide a biomimetic environment, on the micrometric le-
vel three-dimensional architecture with the desired surface properties regarding the in-
tended application within the body, while on the macrometric scale mechanical strength
and physiological acceptability. Nanofibers can be prepared from polymers of both syn-
thetic and natural origin, but among them those being biocompatible and biodegradable
are preferred (2, 9). Although various methods, such as self-assembly, phase separation
or electrospinning, can be used for their preparation, only the electrospinning technol-
ogy, which uses high voltage supply to transform a polymer solution into solid nano-
fibers, is versatile, efficient, widely used and applicative on the industrial scale (Fig. 3)
(10, 11).
Nanofibers in regenerative medicine
Tissue engineering, also named regenerative medicine, is a promising multidiscipli-
nary science field. Its main objective is the development and construction of a biocom-
patible tissue scaffold, which will, in combination with living cells and/or bioactive sub-
stances, renew, replace, maintain or heal damaged cells or tissues and stimulate the
physiological process of regeneration (12). Despite the fact that tissue engineering has
been constantly evolving ever since the first mention of the term in 1987, the clinical use
of tissue substitutes is nowadays still far below expectations (13). The primary idea of
regenerative medicine was to prepare a carrier from biomaterials in the form of the af-
fected tissue or organ, seed it with the patient’s autologous cells and then implant the
entire system in the body (14). However, another strategy is currently in precedence.
This is the application of a porous three-dimensional substitute that has the ability to
mimic the natural extracellular matrix (ECM) by itself (12). The underlying rationale is
that different injuries or pathological conditions cause a change in the ECM in the body
and cells have to restore it during the regeneration process. Unfortunately, physiological
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Fig. 3. Scheme of nanofiber preparation from polymer solution by electrospinning and their poten-
tial use in biomedicine.
ECM formation is often insufficient or even disrupted and it is therefore reasonable to
expect that the application of an ECM analogue will enhance natural tissue repair, since
the tissue will adopt the applied scaffold as its own ECM (5, 15).
Nonetheless, the preparation of an efficient ECM analogue is a tough challenge. A
competent analogue must not only imitate the topography and structural properties of
the natural ECM, but it should also have the ability to connect with the cells in all three
dimensions and promote communication between them (16). The physical structure of
the natural ECM is in nanometer dimensions and consists of three basic groups of ma-
cromolecules. Namely, filamentary structural proteins such as collagen and elastin fibers
(50–500 nm), which provide the structure and strength of the matrix; adhesive glycopro-
teins, which connect the matrix parts with each other and with the cells; and proteogly-
cans and hyaluronan, which provide flexibility and lubrication of the matrix (5). ECM is
the essential and most extensive component of every tissue because it surrounds the
cells and is produced by tissue cells themselves. It is much more than just a physical
support for the cells. ECM also represents a substrate for cell adhesion via specific ligands,
provides and directs cell migration and regulates their growth and functions through a
variety of bioactive factors (14, 15).
Currently, the most promising analogues of ECM are nanofibers, since their nano-
scale fibrous structure mimics the fibrillar elements of ECM in so far the most genuine
way (17). Even more, detailed investigation reveals that the majority of human tissues
and organs on the nanometric level are actually hierarchically organized fibrous struc-
tures (18, 19). Thus, after implantation the nanofibers unite with the surrounding tissue,
provide efficient adhesion of the cells as well as their proliferation, differentiation and
migration, support neovascularization and, owing to their porosity, enable the exchange
of nutrients and metabolites (1, 5, 20).
The biomimetic effect of nanofibers can be further promoted by a proper selection
of the polymer from which they are prepared. For this purpose, polycaprolactone,
poly(lactic acid), poly(glycolic acid) and their copolymers as well as collagen, hyaluronic
acid, natural polymers of ECM and many others have been studied (13). Besides, optimi-
zation of fibers’ thickness, alignment and porosity enable the formation of a micro-
structure that completely fits into a specific place in the body. For example, studies have
shown that a thick layer of nanofibers should be used for a good response to the pulsat-
ing flow in the artery wall (21, 22), while real conditions in the vessels and nerves are
better imitated with structurally oriented, rather than randomly deposited, nanofibers
(Fig. 4) (18, 22). In particular, the arrangement and orientation of nanofibers consider-
ably affect the cell response, since studies have proven that cells grown on aligned fibers
orient in the direction of the fibers and frequently also reflect a higher proliferation rate
(22, 24).
Surface functionalization is an additional way of upgrading nanofibers; it can be
easily achieved by embedment or adsorption of components, such as growth factors and
glycosaminoglycans (hyaluronic acid, dermatan sulphate, chondroitin sulphate, hepa-
rin, etc.). In particular, incorporation of the latter is an important aspect in the pristine
imitation of ECM, since glycosaminoglycans have many crucial features, including link-
ing of collagen fibers and binding of different growth factors (26). Interestingly, beside
these components, live cells have also been incorporated into thicker fibers (27).
298
R. Ro{ic et al.: Nanofibers and their biomedical use, Acta Pharm. 63 (2013) 295–304.
Several independent studies on cell cultures or on experimental animals have al-
ready proven that nanofibers represent a forward-looking approach for the engineering
of various tissues, such as bone, blood vessels, nerves and others (1). Nevertheless, de-
spite numerous scientific publications in this area, clinical studies confirming their effec-
tiveness in humans are not yet available.
Nanofibers as advanced bone substitutes
As damaged bones and osteoporotic fractures are a serious health problem, a signifi-
cant number of researchers focus on the development of nanofibers as bone substitutes
(5). Most drugs used to treat osteoporosis today, such as bisphosphonates, estrogen, ra-
loxifene and calcitonin, only slow the degradation of the bone, while the formation of a
new one is not encouraged (28). Notably, the latter can be significantly influenced by the
application of a substitute made of nanofibers (28, 29). Human bones are made up of 35 %
organic matter, mainly collagen type I, and 65 % inorganic substances, where calcium
phosphate predominates. In view of this, beside the polymer forming the fibrous frame,
advanced bone substitutes include hydroxyapatite, which strengthens the structural in-
tegrity of the substitute and enables good osteoconductivity and binding of the natural
bone components on the substitute (30). In vitro studies have confirmed a high degree of
osteoblast attachment and growth on nanofibers from chitosan and hydroxyapatite as
well as a significantly increased mineralization as soon as in 15 days (31).
Further, different studies have demonstrated the benefit of nanofibers for reparation
of damaged ties between the bones due to their large surface area and porosity (5). In-
vestigations have also compared different systems of the same material for this purpose
and have proven that better attachment and proliferation of human ligament fibroblasts
is achieved on the polyurethane nanofibers than on film and that a progressive collagen
synthesis in vitro is better stimulated when using oriented nanofibers than those ran-
domly deposited (31).
To conclude, nanofibrous bone substitutes currently only improve the quality of
bone integrity due their structure, but the development trend suggests that the next gen-
eration of substitutes will include active substances that will additionally enhance bone
regeneration.
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Fig. 4. Representative figure of: a) randomly collected and b) aligned nanofibers with parallel orien-
tation under scanning electron microscope.
Nanofibers as progressive dressings for chronic wound therapy
One to two percentages of the total population in the industrialized world experi-
ence a chronic wound at least once in a lifetime. Although a number of novel treatments,
such as therapy with hyperbaric oxygen and negative pressure, did improve the results
of their treatments, an extensive and chronic wound still remains a major complication
and cause of death in diabetic and hospitalized patients as well as by those having large
burns (18, 24, 32, 33).
Chronic wounds are defined as all treated wounds that do not heal during an eight-
-week period because their natural healing process is delayed or disrupted. The latter is
most commonly stuck in the inflammatory phase, when secretion of cytokines and
growth factors as well as extensive proteolysis and unsatisfactory neovascularization are
present in the wound (35). The main reason why a chronic wound is not able to close is
the imbalance between the tissue construction and degradation processes at the wound
site and especially inadequate formation of a functional ECM, which otherwise encour-
ages, directs, and organizes the healing. Therefore, the development of modern wound
dressings, which mimic exactly the missing matrix, is the most comprehensible approach
for the treatment of non-healing wounds. For the aforementioned reasons, nanofibers
can be used as efficient ECM analogues. After the application onto the wound, cells will
take the latter as if synthesized by themselves and consequently oriented chemotaxis,
adhesion, differentiation and cell growth will be stimulated as well as the formation and
deposition of a provisional matrix and re-epithelialization (16, 18, 36).
Inclusion of nanofibers as components of a modern wound dressings combines a
number of advantages. They replace elastin and collagen fibers of ECM in terms of shape,
size and mechanical properties, permit drainage of wound exudates, are gas permeable
and prevent wound contamination. Results have shown that the nanofiber topography
itself, regardless of the material nanofibers are made of, has a positive impact on cell be-
haviour since it stimulates cellular regeneration processes (13). Nevertheless, if nano-
fibers are made of hydrophilic materials, they have an added value of providing a moist
wound environment, which is proven to fasten the migration of epithelial cells from the
wound edge toward the center and ameliorate healing (36).
One of the recent studies by Balaji et al. has shown that application of nanofibers
made of proteolysis-resistant angiogenic RAD16-II peptide in diabetic ulcers results in in
situ formation of a provisional matrix composed of nanofibers and ECM elements as
soon as three days after the wound occurrence, which consecutively leads to consider-
ably increased wound closure by endothelial cells and formation of granulation tissue.
After 28 days, the thickness of the reconstituted epidermis is similar to that of the native
skin; there are evidences of hair follicle and absence of hypertrophic scar formation (37).
Of particular interest are also nanofibers made of hyaluronic acid (HA), because
concentration of the latter in the wound increases significantly during the early stages of
the healing process. HA accelerates cell proliferation, induces migration of fibroblasts
and cells of the immune system at the wound site, moderates the inflammatory process,
reduces the scarring intensity and even has antioxidative properties (38). All these ef-
fects are primarily attributable to the physical and chemical properties of HA, especially
its exceptional hydrophilicity, and partly also to the binding on specific receptors located
on the cells and ECM. Comparative research based on histopathological tests has proven
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that wound healing with HA nanofibers is better than with gauze, HA alone or adhesive
dressings, while compared to the antibiotic treatment, no statistically significant differ-
ences were observed (38). In addition, other studies taking into consideration nanofibers
from different polymers and established materials for wound dressings, such as Tega-
derm®, a nylon dressing, and hydrogels, have led to the same conclusion – nanofibers
make the most effective and advanced wound dressings (36).
To even more actively participate in the regeneration process and further enhance
healing, different active substances can be included inside or on the surface of nanofibers
(39). An additional benefit is that with such dressing a wound is treated locally with direct
contact between the drug and tissue, with limited possibility of systemic side effects (40).
Active substances can be incorporated inside the nanofibers, physically adsorbed or
chemically bound to the surface. Of the various loading possibilities, physical entrap-
ment is currently the most widespread, since the drug in the nanofibers is protected
against unfavorable environmental conditions and it offers good control over the drug
release (8). Moreover, incorporation of a drug in nanofibers is relatively easy to perform,
since the drug is simply dissolved in the polymer solution prior to electrospinning and
the formation of an amorphous drug is favoured due to a very limited time being avail-
able for drug recrystallization during the fiber formation (9, 11). A typical release profile
from such nanofibers exhibits an initial burst effect followed by an almost linear, sus-
tained release (1, 5). In addition, core-shell nanofibers can be prepared, which provides a
drug-reservoir system with a shell barrier protecting the incorporated drug and control-
ling the drug diffusion rate.
The first drug that was incorporated into nanofibers from poly(lactic acid) and a co-
polymer of polyethylene and vinyl acetate was an antibiotic tetracycline (41). Since then,
many other antibiotics (40, 42) as well as various antiseptics (43), antifungals (5), non-
-steroidal anti-inflammatory agents (44), anti-cancer drugs (40, 45) as well as biomole-
cules such as proteins (5, 7, 21, 46) and nucleic acids (47) have been built into or ad-
sorbed on nanofibers. For example, Choi and his colleagues bound the recombinant
human epidermal growth factor on the surface of polycaprolactone and poly(ethylene
oxide) nanofibers and proved that the growth factor retained its biological activity (7). In
addition, using an animal model of diabetic ulcers they found out that such dressing
stimulated the proliferation and differentiation of keratinocytes at the early stages of
wound healing, while their phenotype remained unchanged. The in vitro investigation
of Yang et al. indicated that nanofibers loaded with fibroblast growth factor enhanced
adhesion, proliferation and secretion of ECM of mouse embryonic fibroblasts. After an
initial burst effect, a gradual release over about four weeks was achieved, whereas re-
-epithelialization and mature capillary vessels were generated after 14 days (46). The lat-
est approach in managing bacterial infections in chronic wounds is the embedment of
silver nanoparticles as effective antimicrobial agents into nanofibers (48).
CONCLUSIONS
Examples described in this review are only a minor proportion of all the results pro-
ving the great potential and usefulness of nanofibers. On the other side, construction of
a three-dimensional tissue scaffold with suitable thickness, strength and mesh size for
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adequate cell infiltration, which is essential for efficient in vivo application, still remains
an impressive challenge. Nevertheless, nanofibers with their physicochemical properties
and nanotopography display improvements in the fields of tissue engineering, wound
therapy and drug delivery systems. According to the emerging trend, where new dis-
coveries and patents daily promote new knowledge about nanofibers’ ability of faster
and more complete tissue repair, clinical studies are soon to be expected. Consecutively,
the development is anticipated to be directed towards the selection of specific polymer
elements, which will further ameliorate the biomimicry for EMC, as well as to the func-
tionalization of nanofibers for particular purposes and thereby expansion of their appli-
cation areas.
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